Company / R&D Expense
ANAPTYSBIO, INC R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$136.0M
FY2025
5-year range
$80.0M / $163.8M
FY2021-FY2025
Trend
-17.0%
vs FY2024
Sector context
#113 of 210
Health Care
What the data says
At $136M, ANAPTYSBIO, INC's r&d expense ranks #113 of 210 in the Health Care sector. R&D Expense has fluctuated over the past 10 years, ranging from $15M in FY2016 to $164M in FY2024.
Based on SEC 10-K filings.
$136M in FY2025 with a 5-year CAGR of +19.3%.
Improved from $132M to $136M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +19.3%
- 5-Year CAGR
- +19.3%
- 10-Year CAGR
- -
Sector benchmark
#113 of 210 in Health CareTop 54% of 210This company $136.0M Sector average $644.1M
▼
-78.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +19.3%, indicating consistent growth.
- In FY2025, r&d expense decreased 17.0% year-over-year.
- Ranks #113 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $136.0M | -17.0% |
| FY2024 | $163.8M | +23.9% |
| FY2023 | $132.3M | +65.3% |
| FY2022 | $80.0M | -19.4% |
| FY2021 | $99.3M | +76.8% |
| FY2020 | $56.2M | +90.9% |
| FY2019 | $29.4M | -47.6% |
| FY2018 | $56.2M | +224.8% |
| FY2017 | $17.3M | +12.2% |
| FY2016 | $15.4M | -10.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026